![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CONSILIENT HEALTH LTD. CONCLUDES LICENSING/SUPPLY AGREEMENT WITH BENTLEY PHARMACEUTICALS INC.
CONSILIENT HEALTH LTD. CONCLUDES LICENSING/SUPPLY AGREEMENT WITH BENTLEY PHARMACEUTICALS INC.
November 23, 2005
Consilient Health Ltd., an Irish-based, pan-European generic pharmaceutical company announced today that it has entered into a non-exclusive agreement with Bentley Pharmaceuticals, Inc., to distribute and market omeprazole, the generic proton pump inhibitor, used in the treatment of acid-related gastrointestinal disorders, which will be manufactured by Bentley's subsidiary, Laboratorios Belmac, S.A.. Bentley Pharmaceuticals Ireland Limited has recently established a subsidiary in Ireland and received approval from the Irish Medicines Board to market 10 mg., 20 mg., and 40 mg. capsules of generic omeprazole in Ireland.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051122005054&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct